The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
January 22nd 2025
The FDA approved treosulfan, in combination with fludarabine, for patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Specialty Pharmacy Times Focuses on Oncology Trends
February 16th 2013Specialty Pharmacy Times announces the addition of a new department, Oncology Trends. This section will focus on the management of oncology medications under the pharmacy and medical benefits, clinical pathways, pharmacogenomic and companion testing, and clinical practice guidelines in oncology.
Read More
Delivering Evidence-Based Value to Cancer Patients
February 15th 2013Specialty Pharmacy Times spoke with Dr. Neubauer to discuss the intricacies of clinical pathways, including how to reconcile a drug's cost and benefits, the importance of making evidence-based decisions, when to deviate from recommended treatment pathways, and why he thinks all health plans should pay for the routine costs of clinical trials.
Read More
Long-Term Data Confirms One-Year of Adjuvant Trastuzumab as Standard of Care
December 12th 2012Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.
Read More
Medicare Could Have Saved $33 Million on Prostate Cancer Drugs
November 28th 2012By prescribing clinically similar luteinizing hormone–releasing hormone agonists for the treatment of prostate cancer, Medicare could have saved 13% of its total budget for monthly injections, according to a study from the Office of the Inspector General.
Read More
Sanofi Halves the Price of Zaltrap in Response to Criticism from Oncologists
November 13th 2012Sanofi slashed the price of colorectal cancer drug Zaltrap (ziv-aflibercept) in half after 2 oncologists from Memorial Sloan-Kettering Cancer Center publicly balked at the drug's $11,000 price tag in an op-ed in The New York Times.
Read More
The Specialty Pharmacy Pipeline: What's Next?
October 17th 2012In a session at the 2012 Academy of Managed Care Pharmacy Educational Conference, Aimee Tharaldson, PharmD, identified the top specialty drugs in the pipeline and highlighted the most recent therapeutic trends within each medication class.
Read More
FDA Approves Abraxane as a First-Line Treatment for Advanced Non-Small Cell Lung Cancer
October 12th 2012Celgene Corporation today announced the FDA has approved Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
Read More